<SEC-DOCUMENT>0001171843-20-008027.txt : 20201116
<SEC-HEADER>0001171843-20-008027.hdr.sgml : 20201116
<ACCEPTANCE-DATETIME>20201116161508
ACCESSION NUMBER:		0001171843-20-008027
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20201116
FILED AS OF DATE:		20201116
DATE AS OF CHANGE:		20201116

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Genfit S.A.
		CENTRAL INDEX KEY:			0001757064
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38844
		FILM NUMBER:		201317081

	BUSINESS ADDRESS:	
		STREET 1:		PARC EURASANTE
		STREET 2:		885, AVENUE EUGENE AVINEE
		CITY:			LOOS
		STATE:			I0
		ZIP:			59120
		BUSINESS PHONE:		33 3 20 16 4000

	MAIL ADDRESS:	
		STREET 1:		PARC EURASANTE
		STREET 2:		885, AVENUE EUGENE AVINEE
		CITY:			LOOS
		STATE:			I0
		ZIP:			59120
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_111620.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES </B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF
1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of report: November 16, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-38844</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>GENFIT S.A. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Translation of registrant&rsquo;s name
into English) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Parc Eurasant&eacute;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>885, avenue Eug&egrave;ne Avin&eacute;e</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>59120 Loos, France</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of principal executive office)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9746; Form 20-F &nbsp;&nbsp;&nbsp;&nbsp;&#9744; Form 40-F</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT LIST </B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 4%">&nbsp;</TD>
    <TD STYLE="width: 90%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1pt solid"><B>Exhibit</B></P></TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1pt solid"><B>Description</B></P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><A HREF="exh_991.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="exh_991.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release dated November 16, 2020.</FONT></A></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 48%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 43%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GENFIT S.A.</B></FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: November 16, 2020</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Pascal PRIGENT</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Pascal PRIGENT</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="hdr.jpg" ALT="" STYLE="height: 236px; width: 950px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #005478"><B>GENFIT:
New Data Presented at AASLD The Liver Meeting Digital Experience&trade;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 190.65pt; text-indent: -129.55pt; color: #005478"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.25pt"></TD><TD STYLE="width: 18.05pt"><FONT STYLE="font-family: Symbol">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><B>New clinical data on the identification of at-risk NASH using NIS4&trade;
technology alone or in combination with
other non-invasive tests</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 59.3pt; text-align: justify"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.3pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">-</FONT></TD><TD STYLE="text-align: justify; padding-right: 5.95pt"><B>New clinical data on NIS4&trade; technology as a prognostic biomarker
to identify patients with higher likelihood of disease progression</B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.3pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">-</FONT></TD><TD STYLE="text-align: justify; padding-right: 5.8pt"><B>Late breaker abstract on the detection of immune cells in liver tissue
based on a combination of handcrafted and deep-learning approach</B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.3pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">-</FONT></TD><TD STYLE="text-align: justify; padding-right: 5.75pt"><B>Other new NASH data including clinical data supporting the correlation
of NASH activity scores with fibrosis and markers of glucose metabolism, and late breaker abstract presenting final results of
the RESOLVE-IT&trade; interim surrogate efficacy analysis</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #005278"><B>Lille
(France), Cambridge (Massachusetts, United States), November 16, 2020 </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;
GENFIT (Nasdaq and Euronext: GNFT </FONT></B>a late-stage biopharmaceutical company dedicated to improving the lives of
patients with metabolic and chronic liver diseases, today announced that data on NIS4<FONT STYLE="font-family: Times New Roman, Times, Serif">&trade; </FONT>technology
and the complete RESOLVE-IT Phase 3 NASH clinical trial were among those highlighted in five posters at <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>The
Liver Meeting Digital Experience&trade;</I></FONT> (TLMdX), the annual scientific congress of the American Association for
the Study of Liver Diseases (AASLD), that was held virtually from November 13 to November 16, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt"><B>Posters and Presentations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt"><B>Title:</B> <I>Identification of patients with at-risk
NASH or advanced fibrosis using NIS4&trade; alone or in</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt"><I>combination as compared with other testing strategies</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Poster:
</B></FONT># 1519</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Author/s:
</B></FONT>Q. M. Anstee et al.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt"><B>Title: </B><I>Baseline levels of NIS4&trade; and
other fibrosis biomarkers and prediction of histological progression</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt"><I>to advanced fibrosis in NASH</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Poster:
</B></FONT># 1484</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Author/s:
</B></FONT>S. A. Harrison et al.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 92%">GENFIT | 885 Avenue Eug&egrave;ne Avin&eacute;e, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com</TD><TD STYLE="text-align: right; width: 8%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="hdr.jpg" ALT="" STYLE="height: 236px; width: 950px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.65pt 0pt 5.9pt"><B>Title: </B><I>Automated detection of immune
cells in liver tissue based on a combination of handcrafted and deep-learning approach</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Poster:
</B></FONT>#LP35</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Author/s:
</B></FONT>B. Allaert et al.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt"><B>Title: </B><I>RESOLVE-IT&trade; Phase 3 trial of
elafibranor in NASH: final results of the week 72 interim surrogate efficacy analysis</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Poster:
</B></FONT>#LP23</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Author/s:
</B></FONT>S. A. Harrison et al.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt"><B>Title: </B><I>One-year changes in histological
NASH activity scores are correlated with changes in fibrosis and glucose metabolism markers</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Poster:
</B></FONT># 1538</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Author/s:
</B></FONT>V. Ratziu et al.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify">The Liver Meeting<FONT STYLE="font-family: Times New Roman, Times, Serif">&reg;</FONT>
is one of the most important hepatology congresses for the medical and scientific community. It brings together more than 10,000
scientists, gastroenterologists and hepatologists from around the world. Due to the COVID-19 pandemic, the 2020 edition of the
Liver Meeting has become The Liver Meeting Digital Experience&trade; (TLMdX), an online forum for the exchange of groundbreaking
ideas and findings in basic, translational, and clinical research in diseases of the liver and biliary tract, and in liver transplantation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt; color: #005478"><B>ABOUT NIS4&trade;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.7pt 0pt 5.9pt; text-align: justify">NIS4&trade; is GENFIT&rsquo;s
non-invasive, blood-based diagnostic technology, developed to identify patients with non-alcoholic steatohepatitis (NASH) and
significant to advanced fibrosis (F<U>&gt;</U>2), also referred to as at-risk NASH. In January 2019, GENFIT signed a licensing
agreement with LabCorp<FONT STYLE="font-family: Times New Roman, Times, Serif">&reg;</FONT> to make NIS4&trade; technology available
for use in clinical research through their drug development subsidiary, Covance. In September 2020, GENFIT expanded the agreement
to enable LabCorp to develop and commercialize a test based on NIS4&trade; technology for use as a clinical diagnostic across
different practice settings throughout the US and Canada. The test is anticipated to be commercially available in early 2021.
GENFIT continues to explore opportunities to obtain formal marketing authorization of an <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>in
vitro diagnostic</I></FONT> (IVD) version of NIS4&trade; in the U.S. and European markets. For more information, please visit:
https://nis4.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 92%">GENFIT | 885 Avenue Eug&egrave;ne Avin&eacute;e, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com</TD><TD STYLE="text-align: right; width: 8%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="hdr.jpg" ALT="" STYLE="height: 236px; width: 950px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt; text-align: justify; color: #005478"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt; text-align: justify; color: #005478"><B>ABOUT NASH</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.7pt 0pt 5.9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.7pt 0pt 5.9pt; text-align: justify">NASH is a liver disease characterized
by an accumulation of fat (lipid droplets), along with inflammation and degeneration of hepatocytes. NASH is a serious disease
that often carries no symptoms in its early stages, but if left untreated can result in cirrhosis, cancer, and the need for liver
transplant. The prevalence of NASH is rapidly increasing as a result of the growing obesity and diabetes epidemics and is believed
to affect as much as 12 percent of people in the U.S. and six percent worldwide. Because of its asymptomatic nature, NASH is often
undiagnosed, and can only be confirmed through an invasive biopsy. GENFIT is developing an effective non-invasive diagnostic technology
that could help diagnose patients non-invasively and on a large scale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt; text-align: justify; color: #005478"><B>ABOUT GENFIT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt 0pt 5.9pt; text-align: justify">GENFIT is a late-stage
biopharmaceutical company dedicated to improving the lives of patients with cholestatic and metabolic chronic liver diseases.
GENFIT is a pioneer in the field of nuclear receptor-based drug discovery, with a rich history and strong scientific heritage
spanning more than two decades. GENFIT is currently enrolling in a Phase 3 clinical trial evaluating elafibranor in patients with
primary biliary cholangitis (PBC). As part of GENFIT&rsquo;s comprehensive approach to clinical management of patients with liver
disease, the Company is also developing NIS4&trade;, a new, non-invasive blood-based diagnostic technology which could enable
easier identification of patients with at-risk NASH. NIS4&trade; technology has been licensed to LabCorp in the U.S. and Canada
for the development and commercialization of a blood-based molecular diagnostic test powered by NIS4&trade; technology. GENFIT
has facilities in Lille and Paris, France, and Cambridge, MA, USA. GENFIT is a publicly traded company listed on the Nasdaq Global
Select Market and on compartment B of Euronext&rsquo;s regulated market in Paris (Nasdaq and Euronext: GNFT). www.genfit.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt; text-align: justify; color: #005478"><B>FORWARD LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.6pt 0pt 5.9pt; text-align: justify">This press release
contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform
Act of 1995, with respect to GENFIT, including statements regarding the commercial availability of Labcorp&rsquo;s diagnostic
test using NIS4 technology. The use of certain words, including &ldquo;believe,&rdquo; &ldquo;potential,&rdquo;
&ldquo;expect&rdquo; and &ldquo;will&rdquo; and similar expressions, is intended to identify forward-looking statements.
Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the
Company&rsquo;s management, these forward-looking statements are subject to numerous known and unknown risks and
uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the
forward-looking statements. These risks and uncertainties include, among other things, the uncertainties inherent in research
and development, including related to safety, biomarkers, progression of, and results from, its ongoing and planned clinical
trials, review and approvals by regulatory authorities of its drug and diagnostic candidates and the Company&rsquo;s
continued ability to raise capital to fund its development, as well as those risks and uncertainties discussed or identified
in the Company&rsquo;s public filings with the French Autorit<FONT STYLE="font-family: Times New Roman, Times, Serif">&eacute; </FONT>des
march<FONT STYLE="font-family: Times New Roman, Times, Serif">&eacute;</FONT>s financiers (&ldquo;AMF&rdquo;), including
those listed in Section 4 &ldquo;Main Risks and Uncertainties&rdquo; of the Company&rsquo;s 2019 Universal Registration
Document filed with the AMF on May 27, 2020 under n&deg; D.20-0503, which is available on GENFIT&rsquo;s website
(www.genfit.com) and on the website of the AMF (www.amf-france.org) and public filings and reports filed with the U.S.
Securities and Exchange Commission (&ldquo;SEC&rdquo;), including the Company&rsquo;s 20-F dated May 27, 2020. In addition,
even if the Company&rsquo;s results, performance, financial condition and liquidity, and the development of the industry in
which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments
in future periods. These forward-looking statements speak only as of the date of publication of this document. Other than as
required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information
or statements, whether as a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 92%">GENFIT | 885 Avenue Eug&egrave;ne Avin&eacute;e, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com</TD><TD STYLE="text-align: right; width: 8%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="hdr.jpg" ALT="" STYLE="height: 236px; width: 950px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt; color: #005478"><B>CONTACT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt; color: #005478"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>GENFIT
</B></FONT>| Investors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt; text-align: justify">Naomi EICHENBAUM &ndash; Investor
Relations | Tel: +1 (617) 714 5252 | investors@genfit.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>PRESS
RELATIONS </B></FONT>| Media</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt">H<FONT STYLE="font-family: Times New Roman, Times, Serif">&eacute;</FONT>l<FONT STYLE="font-family: Times New Roman, Times, Serif">&egrave;</FONT>ne
LAVIN &ndash; Press relations | Tel: +333 2016 4000 | <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">helene.lavin@genfit.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%">&nbsp;GENFIT | 885 Avenue Eug&egrave;ne Avin&eacute;e, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com</TD>
    <TD STYLE="text-align: right; width: 50%">4</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>hdr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hdr.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $F!*$# 2(  A$! Q$!_\0
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MUM2*&2J)C&X\5#*175,TDJ#;BK01:AFP :$)F-=P@DUSE_#AN*Z:Z8#-85X
MU:HRF8VW%&*FD7 IF*HS&8I*?28H$)3<4_%)B@!N*,4M&:!HC(YI"*>>M--(
M8PU&U3$<5$PI,I$1ZFD%*1S1WJ&:(!4BCFFK3QUJ2T2)UJPG6H$ZU.O6@9(!
MFE%(#3NU!+%%.%- IPH)'"E'6FTX=: '&BBDS0 ZG"FBG=J0A:,TT4Z@ J-F
MQ3ZADI@1R'-5'/:IW/%1[<T&D2-1S5A&*L*$CIZI\U,&;>FWFQ@":[;3IE>,
M$&O-HV*MQ72:3>M'@9XH$>@P.& !JZIP!6%9W@<+6HDV5J2BWYE/62JBOFIX
MR*8RR&H+&HP:<#D4A#'-(*1^M!/%,!6-1LU(S5 SFBPB0L,U+&035/<:EB?!
MYJ9*X)FK X7K5D8-9L;9.<U9$W&,UA*)M&1NQ?ZE/]T4ZHX&S;QG_9'\J>:"
MA#4;FGDU$YH&5Y#S313FZT**FX[$B"IE%,05*!30,4"EQ2BE%,D3%&*=13 ;
MBG4E&:!"T4F:6F(*6DI:8!2&EIIH 0TTTII#0!$XJ G!J=^E5G/-3<=AP-2B
MJX/-3(:=P:)13Q3!3P:8API:3-+0 M%)10 4444""DI:2@8A%,(IYIII@-H#
M4&F$U+!$H:G;JK@XIX-38HE#4[-1@TNZ@&.S2$TF:2F2%+24Z@:$(I,<TZDI
M%"BEI**!"T9I,TW-4(=FES4>:-W%($/S5'5CBU7_ 'Q_(U;#51U=O]$3_KH/
MY&IEL7%ZF3GFGY)%-7&*DXI1)GN,RPI?F(J0 &EQ@5O$R9 $.:794H'-+BK%
M8@VG-/4$5)BEQ0*PSFG"EQS2X% QN:0M3R!3"* #=B@O3#Q32V*+")-U,+4W
M)-.52: #=13_ "Q10(Y5I":$/%(%IRKQBE($*C$MS5M3P*JHO-6 *XYWN=%-
M$ZFGBHE!J91@9K%G7$>@YJ<#BH4'-2@XJ4R["@4T@BFL^#2>96D69R0X]*;N
M/K2%N*@+'?UK>F]3DJ()'YJ O1,V#4&ZNU'..=JKN^*<S9JO,>*8B-Y\9R:K
M/=HIZU!=28!P:PIKI_,(S4LHWVO% X-4IKO.>:S1.Q'6DW%J2$R2>0M6?*-U
M6W4U6E2M$S.2,^9*JG :KTW%4WQFK,FB,]:7%*:.E!(F*0TH.:*!C2.*;BGF
MFFAC$(II%.I#4E(:1Q4+=:G/2HFS04B$CFF]Z<>M##C-0RT IXI@IXJ2R9:G
M4<5 @J=>E QXIXIHIPH)8M** ,TO2@04X=:;3@30 Z@#-&32BAB84[M333@,
MTA"4ZD(VT \4 (3BH9&J1^M5Y30.Q&YS2+3">:>G-,T2+$8J81\9ID0JRHR,
M4T2V0A.36A9NRL*KI'DUH6\/0XJK$W.BT^YX6M^WF#*,FN2@)2M&"[VD9:E8
M:9TR-5F,\5C6]VK #-:"W& *+#N7@W;-/!P*IJY.#FGM(0.M38:98W9HJNLA
M-2@\4Q@PJ!UJ<GBHGZ4"(,TH)--;K2#-#0%B.;::M"4,.*SLU(CE:EQN.YV%
ML?\ 18?]Q?Y5+FH+1LV<!_Z9K_*IC6+1JF(343FI*8PJ64B$TH%*10*@LE2I
MA4*5.*I"8M*!0*451(8IIX&356]FO0-EE;"20_QR-M5?ZG\*PKK0[NZ!EUG6
M D?>./Y4'Y_X5S5J[AI&+;^Y?>_T-J5*,M922_%_<C8GUC3H&VR7L(;TW@G]
M*B'B'2B?^/Z,?7(KEM0C\,P6<EO9"2YNV7",A9B&^O2N<GM+BT*"XA>(N,KO
M7&17D8C-<11>D4UY-NWJ]CU*&6T:BU;7JDK_ "/6(+VVN1F"XBE_W&!J?->.
M)(\;!E8JPZ$'D5OZ9XMOK-E2<_:(?1OO#Z'_ !J\/GM.3M5CR^:U1-?)IQ5Z
M4K^3T_X!Z+FES5#3]3M=3@\VW?</XE/53[BKF:]R$XSBI1=TSQY1E!N,E9CZ
M:329I,U9($TA-!III,!CGBJS=:G:HF%2RT, J9*8!4BBDALD%.I *7%6C,4&
MG TREJ@'YHS3<T9I /HIN:,T +129I,T *:::4TTTP&FF&GD9I-E $=/!I=M
M&*5@%!I<TVDS2L!)FC-1[J4&F _-+FF9HS28T/S1FF9HS2&/S1NIF:;F@"3=
M02*B+4PO31+)2U&:B4Y-2BA@A16?K7%FG_70?R-:%9FO$BQCQ_SU'\C18=S.
MC;BIU-4(I"*M"7BERB;+0QBFDYJ#S\\4!LGK6D40V39I<U$'Q2AZL5R3-&:C
MW4H(IA<?FG;A4)<"HVEHL%RP7'K3"X]:K&0TPR&@+EIF![U&35?S#1N- BT@
MJ>,<U31\&K$4G-(19P**;OHI!<X[> U.$PSBH'0YIBH=U4QHNHX)XJ<,:K11
MXQ5L(>,5RS6IT0=B6,FIU/%0 [>M/#<5A)&\63CI2XS40<=Z&DP*S:-+BO@&
MF$TPOGO3"U.-R9LL=5ZU$!EC4?F8'6D$H[UU4T<=1C9P,U3<L*MNP.<5789!
MKJ6QSE<N1WJM-)Q4\J$51F!%4AE.X;.1FL29!YIYK5G/6LF=@'S2D-$L:9%2
M*@%012C')J3SU]:E,&ASXJK*13WF![U7>0&K3(:N5ISUQ5!\@U<E.:JR#FJ3
M(<2/-*32%3FC ]>:JY'*(#BESS2 #O01CC'-%Q\H9I,@FCGV'XTZ*">Z?$4$
M@ ZL5P*ER'R#,@TF:T'\/ZD,9MI#&PR' X%:FE^![_5\B&:(D=1NY%2Y%*!S
M6/>HW&T$YZ5W ^&E\[&!)L3+[<4V\^'BZ1")-4OUC8G&.]+G*Y&<+UYI/;\A
M7<3_  V=K=;FRU.)H&&<L<$4FE_#2^U)B/ML"LO0;QEJGF+46<0,5(,8KL;O
MX<W=K<-;K<HUPO(0G&ZN=GT#5K2X:*>T=6!].*.8=F54(J4&IO['U.)-XLY7
M7N0IJ#!1MDB,C^C#%%PLR7=TIV<=:C(PP4\GT%*I )!RWM330F2@TF<FF=.I
MQZ"G#-,5B1:<#4)9A2AC0.Q..1148<TX-2$T/!S3L@"H=Q!HWYI"L2YII;%1
M[L4UG-/0!S.*K.<FG$$U&RL*EE(@+_-4L;<U RG=4L6::*-"'K5V,9-4;<Y8
M5IP)DU:,WN6(80<5J6\'R\"H+:('%:L$>*M(ED!AP*KR,4K5:+(JC<1<T6!"
MVMRP/6M9+W@#-8,>4:KD;=.:+#N=!!=>IJP92:QH91N S5Q9<8P>*AH:9IQO
MQUYJ</Q6>CC%6%;B@NY.7IK-Q41;TH+<4$D;/AC33+BFL<DXJ,HQHL IN#GB
MGI([TD5J7/ K2MK0+]X<U,I6!'36(/V"WS_SR7^56,4VV7%K"/1%_E4N*P;-
MT,Q32*FQ32M2RD0$4W'-2E:85YJ;%#UJ9>E1**E6FA,<*\W\>>/;O3M1AT3P
M^/-U(NIE*IO*]P@'<GO[?IUWBG74\.>&[O43@R(NV)3_ !.>%']?H*^;H-7O
M[35UU6*X9;X2&42GD[CU)SUSDUV8>CSWDS@QE?V=HQ>K_(]CM6^)VME6F:QT
MBWQR&3YC^&2?U%37C^%M&93XAU\7EW_%&CEN?]U<D?B:R?[,U/6-)@U/Q;XT
M6TT^:,.+>V=4# C.#C )]@#3=*N?#MK)Y/@SPI/K%TO'VV=<1@^N]OZ 5E7P
ME*L[S2=NVWXET<75HKW&U?N]?DDK_B==8ZE+/$O_  CVAJD+#Y9Y@$4CU]3^
M=97B*TF\@W&IZI#)>+Q';QKP 3S4=W>:K9R"X\7^);/3X&'&G6*Y<^V?O$_3
M-.U":T31C)8:-(EO/@"[N1\[9Y! /(KY_,,-*E2?.[QMIT7R273NSWLOQ"J5
M$XJTNO?YMM[]D<U1117R1]06]/U&?3;I9X'P1U'9AZ&O2M.U.+4K)+B(XSPR
M]U/I7E5;GAG4C9:B(6;$,WRGV/8_Y]:]G*<<Z%54Y/W9?@^YY>98-5J;J17O
M+\4>B;Z=FH%J45]@SY8=2&BBI92&$4TK4A%)BD41[:<!3L4 4 QPI:0&EJD0
MPHHI":H0M)FFEJ;DTP),TN:BS3MU B2BH]U.#4 .I#1F@T#$I:!12 *2EHH
M3%(13J2@"/%&*<::3B@ S29HS24F-"YIV::!3A4E!333L4F* &&F$5*132M4
MB6A4%2@5&E24Q"@5FZVFZS0?]-!_(UIBL_6/^/1/^N@_D: ,-4Q4FWY:.M/'
M YJD253D-4BL:23&ZD& >M6B62[C1O-1EAZTPO[T")_,IIE-0&3WHR3WJ@)=
MY-)R::OO3P:!";2: AI^?2EW9H CV"E""G8HI7 4*!4D?!J,$4X'%(3+.:*A
MWT4KB,%HN.E-6V/7%::PY-*8\' '%.Y:*21D4_[HJUY?M33'ZBLY(T3*AR>:
M!)BK!C["F/;X'%8R1K&1%YE(TOO2M$14#J16;@:<POFG/6G%JKD$4N3BG&!,
MIH<7.:0$DTSFGKDUT11SR=R51Q2.*D133BE;(S*#J3FJ-PA(-:[Q]:I3IP::
M8,YVZ&T&L2Y<9-=!?K@'BN:O&P328(A6?'%)]H/K5'<2]2*#FH*+?G>]'F Y
MJ,1DT%#FG<+",P)P#S4#M\P%.D(4_+P?>F1Q3W+^7! TC'L!57(<1A;YL9QB
MFEE5L $M76:?\.-9U"/S)0+=,9PW4U6>Y@\+7&R[T>2693@.1D&DY#43-L=$
MU+5& MK9C@]<5O6G@/4#=D7BG:!DXKK?#OB^YU2(0Q:)]F$G D"XJAX]\;S>
M&[2.SC!\]^KD?UJ><M0.5$ND:7K*V\NF33*C<G'6O3V@L-9TJ-+:"&UC(''
M:O#K6_UWQG>BUTM/FSS+BI_$%OXE\$[$NM2+AOO8.2*3E<KE2/6O%WB5/#.@
M)9I;%XRNUG*\_A7D^DZUJ$VJLWAB.6:X8Y<<X%,TSXEW(06NJ0+>6K<$R#)
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M9">2E-2(<3SE2I; P<],T\+@9["O2--\/^%/%,+/IC.I_O8^[]:Y[Q)X*N=
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M'@$DX HL%Q*45']H@_Y[1_\ ?8I?M$'_ #VC_P"^A3L+F1)013/M$'_/:/\
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M#5JZ$+KEUGMOC##^=</M/[_X'IJC_P!.U]YTT^CIIOP\N],DG^UQPV4H21E
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M-6A3:<FM3YKW-ZFMSPIH\?B#Q%:Z;/-)%'+NR\>,C"D]_I6'76?#3_D>]/\
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M_A4DVO:=!M\VXV[D#CY&Z'H>E1_:$;7YE^!?]GO:S_$RK#PU>6'@VYT?[?\
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MG)N^SO\ CY^70Y?7!)%K5O,#<*@B(,D,>\@\UH:7?)/B BY:0 DR30[,\_\
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M+XI7.F0_]=Q_Z"U ',PK@"KL:U7B7@5:C&*YYG3!%E%XJ0)3$/%2BN=G4EH
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M*V!5BTU:6U&PKO7IC-0S:;=F1F*%\\X7K55(I8Y0LD3Q_P"\*!,Z2QGC4-<
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M9[;<QXJG);'TK>DAR34#6^>U2P,182O44,".E:C6W/2H9+;@\4FD,].T<_\
M$CT__KVC_P#015T-5/2%QHE@/2VC_P#015OI7.S=$JM4JFH%-3*: )13A3 :
M>* %Q12TAH *4"FT]10,<!3Q2 4X4@"G48I: $HI:*0Q**6B@0TBF$5(:::8
M$)%(!4A% % "!:?B@4Z@!N*,4ZB@!A%,85(::128T0D4Y:5A2"H90X4ZFTM
MPI:2EIB%[4TTN:0FFB6)24$TF:LD6DHS29H 6DHS29H&+2BD%.%2QH*<*0"G
M 5)0M%+BC% "44M% "4E*:2F(0TPTXTTTT)C#3*>::13$-K'\2#.G1_]=A_(
MULXK*\01[[",?]-1_(T,J"NT<NB<U85,GI3XK<\5;2#VK!K4]2$4D5Q$?2I%
MB-75B'I3Q%STJ' ?/8H%<=J@D%:CP^U0O /2I<!J9E,IS493GI6DT(':H6B
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MPCK!_P"9RU3_ +X2NL IX%2ZLOZ2&J,/Z;.2'A#6/^ASU7_OA*7_ (1#6?\
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M4I%<[W-T0[:4+4F*4"D!'MI,5-MII6@"$U+#3&%/BXH M+4HJ)34@H D%*&
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M\5HWJVUOI2HB[IW.6D[U-9ZM]GLOLT,,4@Q\S,.:2V QIV2"W*H,L>M0%U,
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M'_']Y$?VCI_K-HW?=XZYZ<5>---$ZG-T2]!TZ7LW?F;]6)1BCO2BH-0 IP%
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M'.,8IX.%%60PVT$<4;J3=3$-*TS%/+4UC0 TKFFE:7<12%J!B;:7%-+4;J
MCVII/:E,E,+BBP,:4^;-68N"*K;N:G1A@4T2V:UM-C%:4=S@=:PHI,586;WK
M1,EHV_M1]:2.Z^?K6,9\=Z:ES\_6G<D]_P!&?.BV!];>/_T$5H UCZ"^[P_I
MI];6+_T 5JJ:Q9LMB84\5&M2"D M--+2&@"-A43#-3$4PB@" KS3E%/Q2A:
M$Q2&I,4TB@"(U8A/RU$14D5 $X-.%, IPI#'4AHHH 8XXJ(FIGZ5 :8AC&F<
MT\TJI0 S:32A#4X04\)2&0!<5(!4FRC;3$(*<*0"G"@ I<444AB44IH I@)B
MDVT\"G!:0B+;2;*GQ2$4#*Y6DP:G*TA6DT-$0IP%.VT8I6'<3%+124K#N.!I
M::*7-,!:2DS1F@0&FDTI-,-,EA3A3*<#5"'BEIN:7- "YI,T4E(8M%*!2XI
M)BJ.JJ3:KC^^/Y&M#%5=0_X]U_WOZ&E<=CGVC-1&$GK6@PXJ$KFI<A\I5"8%
M&TU9V4FRLV:1T*S)QTIICXZ5;\N@QUFXW-5(H/'@5 >*T98>.*HR(0:PE&QM
M%W'Q.0*N1OCFLP28.*LI+THA*S*E$U(I,U>B:LJ%ZT(CP*[*<KG+4B7U:IE;
MBJR'@5,K5O<YV2YIC49IC&F(**3(HIB/*4?YQ6Y;'<%KF$DY!S6U87'3FO+I
MGJ3-Q,[JLH*JPNIJ[%C'6NN)R2)4%2@"FK@"GKS6B,QC+Q4#)FK)'%1$<T 5
M7'Z5"!^\S[59<<FH",R*OK30F?/OQ"BV>*IQMZUR4$+.Y"GH<UW_ ,4[;R?$
M6_LU<!&_DS-\W!-406)5:7DJ0@[BAF\V$QL0".E7HKU7M3:QJ#WS4"6$-PI>
M238Z]J8B&&]=8Q#O(QZ]Z+C+)O'!]N]1RQ"/</O@=*CBG$T3QD[6'8T ,:TN
M(@MR$R&IMS*&''4=:M6]X[6_D,^=O:F20I)E]N* *ELA;D$XJS)+L4#/XBE5
M=B&J<K$O@4 6EO"_R$L1[FI\!$+CBL^W4-+S5JY8*F!QF@!OE?:6+9%']F3%
M_P!UAR>PJM'.4.".*N0W3#!C<H1R*0T)(CV496:-D8]\=*H!@<EJZVVUN&XM
M_LFH6RO&W60#D51U/1K&.'S[.;=GG:>U 6,2&(S'"9)]JM3JULJ@?>]>]6-/
M41*6<C(]*I7DIENB0<B@#3M=<EB54W!@.NZB>:TN7WI%MD[GM6&W!XZU=M?D
M&XCB@+EV[$UQ;B.,[L=JQY(WADVRH4X[BK<5[)'.65L 'O6K!J-M>?)=PAO]
MK% S&LXP6W#H*+FXS)M[5T$^AVTL'FV-QEC_  5S=Q%-;2%)XCGUH"Q-#?20
MXV%@?7-;EMKS,HBN0KK[BN>MK<W,Z1J/E/7VJUJ-LMC(J)\QQ0P-*_TBVNO]
M(LVVGNM8@M)([I$=2"3SGO4T&HS0KPV!Z5:CN3<,'.,T+0"YK$5I;V4:Q+B0
MCG%<XLDB\Y/%=#+I[:@@V3#<.V:RKG3KNU/S0%E_O"G<+"V]U)*RAW^7IBM:
M*>V#^3/&3'Z@UE6P" L<;@.AJM-(9I-V2#Z4F!O-X;BO6+Z;.-Y^[&>M49=/
MNM*E*7L#1GL>QJM::C-;RJ\;M&R],5TBZV^IQ_9[XH[X^4FC8=SE+AB[%B>.
MU-1GR%5NO:M&[TORR[PY8TW2[<37(\Q<E>M A]O>26#C!8'TSQ5Z6:VOTS+@
M/CK6;K!3[443H!VJDF0>#TIDFG8P>3?JRCY%.<FEUR]6ZNP%_AJ2R?8H=SN
MYQ6BUIINIQ95A'+4C.=A1I74+SSR!6TMW':%%. .ZFFOI,NFQM,GSCU%948:
M\GR22V>*!G2WJVFK:?A 8IE'!]::=&'_  C\,JX\\-AS[5D6=T8+EX902_\
M#6\TDITHJ5+!NH7M0,NV(%U"=*A?]^P&,]ZU_&4=M#H6G62E#=P@"0CUK%\,
M13VETMQ<KM"J=C'K6;?W#7>MRDEPN=Q#=S4]0Z&O8+FWYY/%6?+!ZBF6/$/
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MJ.&..123U-1,[B+9+VJ&)COX- %@Q>4Y*U#+YC'+ XJVA 3+&CS8VX.* *"
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MWKYTO_QNJR_L^>+E;/\ :6B_]_I?_C=%% $R? /Q>J<ZGHQ'IY\O_P ;J<_
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D_OH_X58CMF'=:**=D2Y-DWE'U%'EMZBBBJ)#RV]11115 ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
